Track topics on Twitter Track topics that are important to you
BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.
Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open https://www.bioportfolio.net/report/23346-biochannel-publish-content-on-products-technologies.html
Interested? Contact firstname.lastname@example.org
Prostate cancer is the most common cancer in men in the UK; affecting 250,000 men. Risk factors for prostate cancer include age (average age at diagnosis is 70), a family history and a Caribbean or African ethnicity. Treatment options depend on whe...
Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and a well-known imaging biomarker for staging and monitoring therapy. PSMA represents an attractive antigen for...
On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prostate cancer (CPRC) following failed Taxotere (docetaxel) ...
Endocrine disrupting chemicals (EDCs) consist of a diverse group of industrial chemicals and pharmacological agents. Evidence is accumulating that environmental chemicals (ECs) including endocrine-disrupting compounds (EDCs) can alter female repro...
Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in the urine, in the tumor tissue, or in other tissues. Diff...
Luteinizing hormone (LH), a gonadotropin, stimulates the gonads - in males, the testes, and in females, the ovaries. It is essential for reproduction, and secreted from cells in the anterior pituitary called gonadotrophs. In females, ovulation of mature ...
Neoadjuvant therapy is the administration of therapeutic agents before the main treatment. One example is neoadjuvant hormone therapy prior to radical radiotherapy for adenocarcinoma of the prostate. The aim of neoadjuvant therapy is to reduce the size o...
Epithelial cell adhesion molecule (EpCAM; CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression of EpCAM has ...
UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It was designed to detect gains and losses that frequently...
BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- BioPortfolio Limited ...